2018年2月28日星期三

Emerging opportunities for the treatment of metabolic diseases: glucagon-like peptide-1 based multi-agonists

Emerging opportunities for the treatment of metabolic diseases: glucagon-like peptide-1 based multi-agonists

B FinanC ClemmensenTD Müller - Molecular and cellular endocrinology, 2015 - Elsevier
Abstract Obesity is a pathogenic gateway to the metabolic syndrome and the complications
thereof, thus interventions aimed at preventing or reversing the metabolic derangements
underlying obesity hold great therapeutic promise. However, the complexity of energy


For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:
*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.
*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.
*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.
*Peptide Salt: TFA, Desalt, Acetate, HCl.
*Peptide Purity: From crude to >99.5%.
*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.
*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.

Eva He
eva@pepmic.com
Pepmic Co., Ltd
www.pepmic.com


没有评论:

发表评论